News | July 26, 2023
Syngene Q1 FY 2024 revenue up 26% to Rs. 832 crores, PAT up 26% to Rs.93 Cr
Acquisition of biologics manufacturing facility in Bangalore to complete by the end of the third quarter in FY 24
Acquisition of biologics manufacturing facility in Bangalore to complete by the end of the third quarter in FY 24
The approved product has an estimated market size of around US$ 210 million for the twelve months ending May 2023
Zurletrectinib was developed to treat advanced or metastatic solid tumors harboring NTRK fusion genes
Tiotropium (as bromide monohydrate) 18 micrograms powder for inhalation in capsule
Erdafitinib is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma
The approval allows treatment of heart failure patients irrespective of the ejection fraction based on new trial DELIVER conducted by AstraZeneca
Good momentum in commercial CDMO business
The Long-term Safety Trial was approved to be conducted by China National Medical Products Administration (NMPA) on 18 April 2023
Pfizer will make upfront and milestone payments, as well as pay royalties on sales of resulting therapeutics
Shivalik Rasayan Limited has issued LOA to Medicamen Biotech to use its DMF grade Bortezomib API for formulation of Bortezomib injection 3.5mg/ vial
Subscribe To Our Newsletter & Stay Updated
